Abstract: Methods for preparing pigmented and nonpigmented powder coating compositions are disclosed. The methods generally involve the use of dispersions comprising a fluoropolymer.

Abstract: A non-dripping, flame retardant, fluoropolymeric composition comprising: (a) a fluoropolymeric base polymer; (b) at least one char forming agent; and (c) a compatibilizer agent. The fluoropolymeric base polymer is preferably selected from the group consisting of PVDF (polyvinylidene fluoride), ECTFE, poly-ethylene chlorotrifluoroethylene, and ETFE poly-ethylene tetrafluoroethylene. Such compositions are especially useful for appliance wire, aerospace/military wire, cable raceways, blown fiber tubes, fire alarm cables, circuit integrity cables, fiber optic distribution cables & breakout components, heat tracing cable jacket, stage lighting cable, industrial cable, shipboard cable (military & passenger), shielded cable jackets.

Abstract: The present invention relates to a composition acting as coupling agent between fillers and peroxidically crosslinking elastomers in rubber compounds, which comprises, as component comprising silicon compounds, a mixture a) of vinylalkoxysiloxanes with alkylalkoxy-siloxanes, or b) of vinylalkoxysiloxanes with phenylalkoxy-siloxanes, or c) of vinylalkoxysiloxanes with phenyl/alkyl-alkoxysiloxanes or d) of acrylic or methacrylic alkoxysiloxanes with alkylalkoxysiloxanes, or e) of acrylic or methacrylic alkoxysiloxanes with phenylalkoxysiloxanes, or f) of acrylic or methacrylic alkoxysiloxanes with phenyl/alkylalkoxysiloxanes, or g) of at least one co-oligomeric organosiloxane which, as organofunctional groups, bears at least one group from the series vinyl, acrylic and methacrylic, and at least one group from the series alkyl and phenyl, and at least one alkoxy or hydroxy group.

Abstract: This invention relates to a room temperature curable composition containing, inter alia, diorganopolysiloxane(s) and organic nanoclay(s), the cured composition exhibiting low permeability to gas(es).

Abstract: Epoxy adhesive compositions contain an epoxy resin, rubber modification, a toughener and a curing agent. The tougher has capped epoxide-reactive groups, and at least one polytetrahydrofuran block having a mass of 2200-4500 daltons. The selection of toughener in a rubber-modified epoxy-based structural adhesive provides for very good low temperature performance.

Abstract: The present invention provides curable hot melt compositions including reactive polymers, which are reinforced by organic polymers to impart higher tensile strength and elongation to the compositions upon cure. In particular, the present invention provides curable hot melt compositions including a silicone urea based polymer and a reinforcement polymer. In some embodiments, the compositions cure upon exposure to moisture and/or radiation. The compositions may be used, for example, as sealants or adhesives.

Abstract: Lithium-terminated polymers of one or more conjugated dienes and of one or more mono alkenyl arenes are coupled by reaction with an alkoxy silane coupling agent having the formula Rx—Si—(OR?)y, where x is 0 or 1, x+y=4, R and R? are the same or different, R is selected from aryl hydrocarbon radicals, linear alkyl hydrocarbon radicals and branched alkyl hydrocarbon radicals, and R? is selected from linear and branched alkyl hydrocarbon radicals, such that the resulting polymer composition contains less than about ten weight percent of uncoupled polymer diblock. The polymer compositions are subsequently selectively hydrogenated, and are useful in a variety of compounds and end use applications.

Abstract: Thermoplastic vulcanizates having improved physical properties, including extrusion surface roughness can be achieved by a method that includes a first processing step to form a fully cured TPV base, a cooling step wherein the fully cured TPV base is solidified and a second processing step which imparts improved physical properties including improved extrusion surface roughness to the resultant TPV. The method may be adapted for use in conjunction with a peroxide curing agents to protect a portion of the thermoplastic, which may be polypropylene, from degradation by the peroxide curing agent. The adaptation to the methods may include the addition of a portion of the thermoplastic to the TPV after the peroxide curing agent has been added. The adaptation may also include one or more devolatalization steps with or without the addition of a stripping agent.

Abstract: A process for producing a modified polymer rubber comprising the steps of: (1) polymerizing a conjugated diene monomer or a combination thereof with an aromatic vinyl monomer in a hydrocarbon solvent, in the presence of an alkali metal catalyst or a specified alkali metal compound, to form an alkali metal end-carrying active polymer, and (2) reacting the alkali metal end-carrying active polymer with a specified isocyanurate compound or a combination thereof with a specified coupling agent in a hydrocarbon solvent.

Abstract: A multimodal polyethylene composition having at least two polyethylene components, wherein each component has a molecular weight distribution of equal to or less than about 5, one component has a higher molecular weight than the other component, and the higher molecular weight component has an “a” parameter value of equal to or greater than about 0.35 when fitted to the Carreau-Yasuda equation with n=0.

Abstract: A process for the preparation of a functionalized, coupled or starred block copolymer which is usable in a sulphur-cross-linkable rubber composition of reduced hysteresis in the cross-linked state, one at least of said blocks consisting of a polyisoprene and at least one other block consisting of a diene elastomer other than a polyisoprene the molar ratio of units originating from one or more conjugated dienes of which is greater than 15%.

Abstract: This invention is directed to fluorinated acrylate compositions, which are suitable for use as low shrinkage, low absorbance refractive index matching adhesives for use in “pig-tailing” polymeric integrated waveguides to optical fiber bundles.

Abstract: This invention relates to an aqueous based process for the preparation of intercalated and/or exfoliated natural or synthetic clays using block copolymers in latex form containing at least one non-polar block and one or more cationic blocks, wherein the block copolymers are prepared by an emulsion controlled free radical polymerization method.

Abstract: An addition-curable organopolysiloxane resin composition having, in a state of cued body, a hardness of 60 to 100 at 25 degree C. and 40 to 100 at 150 degree C. as measured in accordance with the provisions of ASTM D2240-86, said composition comprising: (A) 100 parts by weight of an organopolysiloxane resin comprised of at least alkenyl groups and phenyl groups; (B) 10 to 50 parts by weight of an organooligosiloxane comprised of at least alkeyl groups and phenyl groups; (C) 20 to 100 parts by weight of an organohydrogenoligosiloxane of organohydrogenpolysiloxane; and (D) an addition-reaction catalyst in a catalytic quantity; an optical material that is comprised of a cured body produced from aforementioned components (A), (B), and (C) and possesses the aforementioned characteristics.

Abstract: A process for controlling a continuous gas phase exothermic process in a reactor comprising: (i) effecting a gas phase exothermic reaction under a set of operating conditions in the presence of a cooling agent, the cooling agent having a pre-selected concentration and feed rate of an induced cooling agent; (ii) determining a maximum production rate (I) without regard to limitations due to the cooling agent under the operating conditions; (iii) determining a maximum production rate (II) with regard to limitations due to the cooling agent under the operating conditions; (iv) calculating an optimal concentration of the induced cooling agent such that the difference between (I) and (II) is minimized; and (v) adjusting the feed rate of the induced cooling agent to achieve the concentration value calculated in (iv).

Abstract: The present invention is directed to novel flame retardant monomers and polymers, wherein the flame retardant properties of the polymers are provided by functionality in pendant groups attached to a polymer backbone (as opposed to the polymer backbone itself possessing flame retardant properties. The present invention is also directed to methods of making such polymers and monomers, and articles of manufacture incorporating such monomers and polymers.

Abstract: Processes for making temporary wet strength additives, more particularly, processes for oxidizing a homo-crosslinking monomeric unit present in a polymer having a homo-crosslinking monomeric unit and a cationic monomeric unit to produce a temporary wet strength additive are provided.

Abstract: A curable composition having good curability and adhesion comprising: (A) an reactive silicon group-containing organic polymer, (B) a titanium chelate represented by the general formula (1) or (2) and (C) a high molecular weight plasticizer having a number average molecular weight of 1,000 to 15,000. General formula (1): wherein each of n R1s is independently a substituted or unsubstituted hydrocarbon group having 1 to 20 carbon atoms, each of (4-n) R2s is independently hydrogen atom or a substituted or unsubstituted hydrocarbon group having 1 to 20 carbon atoms, each of (4-n) A1s and (4-n) A2s is independently —R3 or —OR3 where R3 is a substituted or unsubstituted hydrocarbon group having 1 to 20 carbon atoms, n is 1, 2 or 3. General formula (2): wherein R2, A1 and A2 are the same as defined above, R4 is a substituted or unsubstituted divalent hydrocarbon group having 1 to 20 carbon atoms.

Abstract: A resin that may be used, for example, in dental impression materials, and a method of making the resin. The resin comprises an alkoxy-siloxane polyester or polyether carboxylate backbone functionalized with at least two cycloolefin groups capable of undergoing a metathesis reaction. The method of making the resin comprises reacting a hydride terminated siloxane with a polyether or polyester diol containing propylene oxide and ethylene oxide fragments, and a cycloolefinic group functionalized hydroxyalkyl carboxylic acid ester, in the presence of a Group 3 or 13 catalyst.

Abstract: Processes for polyurethane polymerization are provided. The processes use polysilyl derivatives of germanium and tin as catalysts. Polyurethanes made using the catalysts have increased gel times as compared to polyurethanes made using conventional processes.

Abstract: The invention relates to polyaldimines which may be obtained from at least one polyamine (A) with aliphatic primary amino groups and at least one aldehyde (B). Said polyaldimines are odorless as are the aldehydes (B) produced by hydrolysis thereof. The invention further relates to methods for production of said polyaldimines and aldehyde (B) and methods for hydrolysis of the polyaldimine. The use of said polyaldimine in compositions as adhesive, sealant, coating or covering agents is disclosed. Said polyaldimines are characterized in being odorless, rapidly hydrolyzed on contact with water, no detectable odors being generated after hydrolysis thereof and stable to storage with the exclusion of water in compositions which contain components reactive towards amines.

Abstract: A sulfonated aliphatic-aromatic copolyetherester that comprises the polymerization product of 80.0 to 20.0 mole percent of an aromatic dicarboxylic acid or an ester thereof based on the total moles of dicarboxylic acid or ester thereof, 20.0 to 80.0 mole percent of an aliphatic dicarboxylic acid or an ester thereof based on the total moles of dicarboxylic acid or ester thereof, 0.1 to 10.0 mole percent of a sulfonate component, 99.9 to 91.0 mole percent of a first glycol selected from the group consisting of ethylene glycol, 1,3-propanediol and 1,4-butanediol based on the total moles of glycol, 0.1 to 4.0 mole percent of a poly(alkylene ether) glycol based on the total moles of glycol, 0 to 5.0 mole percent of an other glycol based on the total moles of glycol, and 0 to 5.0 mole percent of a polyfunctional branching agent.

Abstract: The present invention provides a compound having a formula: where R1 is selected from the group consisting of alkyl, CH2(OC2H4)OCH3, and —(OC2H4)OCH3; n is 0-4; Olig is an oligomer having a formula: -L-O-PAGR.R2]q where L is a optional linker moiety selected from the group consisting of —CH2O—, —CH2OX—, —OX—, —C(O)—, —C(O)X, —NH—, —NHC(O)—, —XNHC(O)—, —NHC(O)X—, —C(O)NH—, —C(O)NHX—, and where X is alky1-6 or is not present, Y is N or O or is not present, and R3 is alkyl1-6; PAG is a linear or branched polyalkylene glycol moiety; R2 is an alkyl1-22 capping moiety if X is present or alkyl2-22 if X is not present; and q is a number from 1 to the maximum number of branches on PAG; and m is 1-5.

Abstract: The present invention relates to a fusion protein comprising IGF-I or an IGF-I variant N-terminally linked to the C-terminus of a propeptide. The invention relates also to a method involving the use of the aforementioned fusion protein in the production of a lysine-PEGylated IGF-I or IGF-I variant. The method comprises the steps of cultivating a prokaryotic host cell comprising an expression vector containing a nucleic acid encoding the fusion protein and causing the cell to express the fusion protein, recovering and PEGylating said fusion protein, cleaving said PEGylated fusion protein with IgA protease, and recovering lysine-PEGylated IGF-I or IGF-I variant. The invention relates also to a lysine-PEGylated IGF-I or IGF-I variant produced using the above method. In addition, the invention relates to a method for treating a neurodegenerative disorders like Alzheimer's Disease using the lysine-PEGylated IGF-I or IGF-I variant and a composition comprising the lysine-PEGylated IGF-I or IGF-I variant.

Abstract: The invention relates to chimeric recombinant polypeptides, preferably therapeutic polypeptides, for example cytokines or antibodies, which are engineered to include a signal sequence for the attachment of glycosylphosphatidylinositol; cells expressing said polypeptides and methods to manufacture said polypeptides.

Abstract: The present invention provides a method for testing an agent for its ability to inhibit binding between fibroblast growth factor (FGF) and heparan sulfate, comprising the steps of: interacting in solution immobilized FGF on a solid support with the agent and labeled heparan sulfate, and detecting the presence or absence of label in the solution remote from the solid support.

Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.

Abstract: The invention provides caspase recruitment domain (CARD)-containing polypeptides, CARD, NB-ARC, ANGIO-R, LRR and SAM domains therefrom, as well as encoding nucleic acid molecules and specific antibodies. The invention also provides related screening, diagnostic and therapeutic methods.

Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.

Abstract: The present invention provides an genetically engineered cDNA of the rat bcl-x gene, which has at least one substitution selected from the substitutions that change residues 22 Tyr to Phe, residues 26 Gln to Asn and residues 165 Arg to Lys, in the coding region of rat bcl-x cDNA of SEQ ID NO: 1, a recombinant vector containing the engineered cDNA, a cell into which the recombinant vector was introduced, and an improved protein of Bcl-xL. The improved protein of Bcl-xL is useful as an ingredient for remedies for various diseases accompanied with cell death since it effectively inhibit cell death such as apoptosis.

Abstract: The present invention relates to a method of purifying a protein of interest from its fusion analog, comprising obtaining a protein solution comprising a protein of interest and its fusion analog; adjusting the pH and/or ionic strength of the protein solution with an appropriate buffer for use with a Hydrophobic Charge Induction Chromatography (HCIC) resin, contacting the protein solution and HCIC resin column to allow binding of the protein of interest and its fusion analog, washing the resin and eluting the protein of interest from the resin by a pH gradient; wherein the protein of interest is substantially free of its fusion analog.

Abstract: The present invention relates to novel inhibitors of aminoglycoside 6?-N-acetyltransferases, more specifically, AAC(6?)-li and AAC(6?)-ly, as well as compositions and uses thereof. Furthermore, the present invention relates to synthetic methodologies for preparing the inhibitors of aminoglycoside 6?-N-acetyltransferases.

Abstract: The invention relates to a process for preparing alkylpolyglycosides from monomeric glycosides, oligo- or polyglycosides and alcohols according to the general scheme (Glyc-O)zH+R1—OH?(Glyc-O)z?R1 where z?1, z??z, preferably from 1 to 10, (Glyc-O)— is a glycoside radical, R1 is a hydrocarbon radical which optionally contains multiple bonds and/or heteroatoms, which comprises carrying out the reaction under supercritical conditions with regard to the alcohol, preferably at pressures and temperatures which are at least 5% above the critical parameters, the alcohols serving both as the solvent and as reactants.

Abstract: Disclosed herein is an isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 1. The isolated polypeptide binds to the DNA binding domain located from ?550 to ?487 in the promoter of the human TNF-? gene. Additionally, the level of the mRNA transcript encoding the isolated polypeptide is substantially increased in response to LPS stimulation in cultured THP-1 cells.

Abstract: Anti-angiogenic polypeptides A61 or p22 are disclosed. Also disclosed are methods of making the polypeptides and methods of treating subjects having angiogenic diseases or conditions.

Abstract: Disclosed are the complete polyunsaturated fatty acid (PUFA) polyketide synthase (PKS) systems from the bacterial microorganisms Shewanella japonica and Shewanella olleyana, and biologically active fragments and homologues thereof. More particularly, this invention relates to nucleic acids encoding such PUFA PKS systems, to proteins and domains thereof that comprise such PUFA PKS systems, to genetically modified organisms (plants and microorganisms) comprising such PUFA PKS systems, and to methods of making and using the PUFA PKS systems disclosed herein. This invention also relates to genetically modified plants and microorganisms and methods to efficiently produce lipids enriched in various polyunsaturated fatty acids (PUFAs) as well as other bioactive molecules by manipulation of a PUFA polyketide synthase (PKS) system.

Abstract: The invention provides, biologically active spinosyns, hybrid spinosyn polyketide synthases capable of functioning in Saccharopolyspora spinosa to produce the spinosyns, and methods of controlling insects using the spinosyns.

Abstract: The present invention relates to improved antibodies against tumor surface antigens and their use in the treatment of tumors. Of particular interest are highly stable, humanized, high affinity antibodies against carcinoembryonic antigen (CEA), especially the antibody we have termed sm3E, which is derived from the scFv antibody MFE-23. Such antibodies have the potential for improved therapeutic efficacy.

Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies.

Abstract: The inventors have isolated cloned cDNA encoding the RNA genome of Human Immunodeficiency Virus type 1 (HIV-1). Various clones are described, which encode different regions of the genome, including those regions encoding viral antigens or proteins. Hybridization results indicate the difference between the HIV-1 clones and those of HTLV-I and HTLV-II. The inventors have also produced a restriction map of the entire cloned genomic sequence in order to facilitate further subcloning and using the restriction fragments in other hybridization tests and in methods to express encoded sequences.

Abstract: The present invention provides single-stranded and double-stranded oligonucleotides comprising at least one aralkyl ligand that improves the pharmacokinetic properties of the oligonucleotides. The aralkyl ligands of the present invention include naproxen, ibuprofen and derivatives thereof. The present invention also provides methods for modulating gene expression using the modified oligonucleotide compounds and compositions comprising those modified oligonucleotides.

Abstract: The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases respiratory conditions and hearing disorders based upon inhibition of the RTP801L gene and/or protein.

Abstract: This invention relates to a method for preparing a sucrose-6-ester.

Abstract: Methods for cell lysis and purification of biological materials, involving subjecting a sample to high pressure. Also featured is an apparatus for practicing the methods.

Abstract: Novel enzymatic substrates of the general formula below: reaction media containing the same and their use for detecting and/or identifying and/or quantifying microorganisms expressing at least one peptidase activity.

Abstract: Disclosed are processes for the preparation of fused piperazin-2-one derivatives of general formula (I) wherein the groups R1 to R5, A1 and A2 have the meanings given in the claims and in the description, particularly the preparation of 7,8-dihydro-5H-pteridin-6-one derivatives and intermediates thereof.

Abstract: The invention relates to compounds such as where P is a nitrogen-protecting group, and to processes for preparing these compounds.

Abstract: The present invention provides novel fused ring heterocycle kinase modulators and methods of using the novel fused ring heterocycle kinase modulators to treat diseases mediated by kinase activity.

Abstract: This invention relates to N and O-protected, optionally substituted ?-heteroaryl-?-alanine compounds of the structural Formula I, wherein each of the variables is as set forth in the specification, methods for producing and using the same.

Abstract: The invention provides compounds of formula (I): wherein E, A, B?, R6, R7, R8, and R9 are defined in the specification which compounds exhibit anticancer activity and are useful for treating cancer.